Skip to main content

Benefits of Dual Treatment for MCL

December 09, 2020

constantine tamConstantine Tam, MD, director of Hematology, St Vincent Hospital, discusses the phase 3 SYMPATICO study that examined the use ibrutinib plus venetoclax for the treatment of mantle cell lymphoma. 


Agree or disagree with an article? Share your professional thoughts on an article you read.

Your Name
14 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Back to Top